Penetration of clarithromycin into lung tissues from patients undergoing lung resection
Open Access
- 1 April 1994
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 38 (4) , 876-878
- https://doi.org/10.1128/aac.38.4.876
Abstract
The concentrations of clarithromycin and its active principal metabolite, 14-(R)-hydroxy-clarithromycin, were determined in lung tissue obtained during lung resection and compared with concomitant concentrations in plasma. Concentrations of the parent and metabolite were determined by high-performance liquid chromatography. The 15 patients studied were given 500 mg orally every 12 h for a minimum of five doses to achieve steady-state concentrations. The mean concentrations of clarithromycin and 14-(R)-hydroxy-clarithromycin in plasma just prior to the final dose were 1.38 and 0.67 micrograms/ml, respectively, and those 4 h after the final dose (at the time of lung resection) were 1.89 and 0.80 microgram/mL, respectively. The concentrations of the parent and metabolite in lung tissue at the time of lung resection averaged 54.3 and 5.12 micrograms/g, respectively, with a mean calculated ratio of concentrations of the parent to metabolite being 11.3 in lung tissue and 2.4 in plasma. Clarithromycin and its active metabolite are extensively distributed into human lung tissue.Keywords
This publication has 13 references indexed in Scilit:
- Simultaneous determination of clarithromycin and 14(R)-hydroxyclarithromycin in plasma and urine using high-performance liquid chromatography with electrochemical detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1991
- Activity of clarithromycin and its principal human metabolite against Haemophilus influenzaeAntimicrobial Agents and Chemotherapy, 1991
- Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humansAntimicrobial Agents and Chemotherapy, 1990
- New directions for macrolide antibiotics: pharmacokinetics and clinical efficacyAntimicrobial Agents and Chemotherapy, 1989
- New directions for macrolide antibiotics: structural modifications and in vitro activityAntimicrobial Agents and Chemotherapy, 1989
- A new macrolide, TE-031 (A-56268), in treatment of experimental Legionnaires' diseaseJournal of Antimicrobial Chemotherapy, 1989
- Clinical Pharmacokinetic Properties of the Macrolide AntibioticsClinical Pharmacokinetics, 1989
- Comparative in vitro activities of new 14-, 15-, and 16-membered macrolidesAntimicrobial Agents and Chemotherapy, 1988
- Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteriaAntimicrobial Agents and Chemotherapy, 1987
- In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolideAntimicrobial Agents and Chemotherapy, 1986